FDA Considers Whether Naloxone Devices Should Contain Standard Dose of Drug

October 13th, 2016

A meeting between the Food and Drug Administration and the pharmaceutical companies that make the anti-overdose, life-saving medication naloxone could alter the drug’s pricing as well as how available it will be to the general public. The FDA will use the meeting to determine whether naloxone devices distributed in communities should contain a standard dose of the drug and what the standard dose should be.

Read Details

Posted in Content

A Project of the Governor's Institute on Alcohol & Substance Abuse and the North Carolina Society of Addiction Medicine.
Funded wholly or in part by the federal Substance Abuse Prevention and Treatment Block Grant Fund (CFDA #93.959) as a project of the NC Division of Mental Health, Developmental Disabilities & Substance Abuse Services.